RXII $.98 ASCO Blockbuster results RXII could be $3 in no time like ZLCS and ACAD. RXII has a blockbuster cancer vaccine with unprecedented results approved for an SPA. The vaccine reduced breast cancer recurrance from 14% to 2%. ober a 2 year period. That trumps DNDN. Updated results at ASCO. Only 30 MM float and $20 MM cash. Market valuing thus vaccine at basically 0.